Alabama Pharmacy Board Defense Attorney – Pharmacist Hearing Upcoming? Call Today – Mibelas 24 Fe Tablets and Professional Samples of BRILINTA Tablets Recalled

14738_graphic_standard_070616Alabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

Alabama Pharmacy Board Defense Attorney – Pharmacist Hearing Upcoming? Call Today – Mibelas 24 Fe Tablets and Professional Samples of BRILINTA Tablets Recalled – (866) 348-2889

Lupin Pharmaceuticals, Inc, of Baltimore, MD, has voluntarily recalled one lot of Mibelas™ 24 Fe (norethindrone acetate and ethinyl estradiol 1 mg/0.02 mg chewable and ferrous fumarate 75 mg) tablets. The affected product was distributed nationwide in the US to wholesalers, clinics, and retail pharmacies. The recalled lot number L600518 expires May 2018 and the National Drug Codes are 68180-911-11 (wallet of 28 tablets) and 68180-911-13 (carton of three wallets). As noted in the safety alert, a confirmed market complaint indicated a packaging error, where the blister was rotated 180 degrees within the wallet, reversing the weekly tablet orientation and making the lot number and expiration date no longer visible. The first four days of therapy would have four non-hormonal placebo tablets as opposed to the active tablets. To date, no adverse events have been reported.

AstraZeneca voluntarily recalled one lot of professional (physician) sample bottles containing eight tablets of BRILINTA® (ticagrelor) 90 mg tablets. The product was distributed to physicians in the US between March and April 2017. The recall affects lot number JB5047. As indicated in the safety alert, the recall follows a report that a professional sample bottle containing eight tablets of BRILINTA 90 mg also contained another medicine called ZURAMPIC® (lesinurad) 200 mg tablets, which is also manufactured by AstraZeneca. To date, AstraZeneca has not received any reports of adverse events related to this recall.

CLICK HERE TO CONTINUE READING

This entry was posted in Pharmacist and tagged , , , . Bookmark the permalink.

Comments are closed.